{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T02:17:45Z","timestamp":1789438665899,"version":"build-2803163510"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T00:00:00Z","timestamp":1768694400000},"content-version":"vor","delay-in-days":3187,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Novartis Pharma AG"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Patients admitted for acute heart failure (AHF) experience high rates of in-hospital and post-discharge morbidity and mortality despite current therapies. Serelaxin is recombinant human relaxin-2, a hormone with vasodilatory and end-organ protective effects believed to play a central role in the cardiovascular and renal adaptations of human pregnancy. In the phase 3 RELAX-AHF trial, serelaxin met its primary endpoint of improving dyspnoea through day 5 in patients admitted for AHF. Compared to placebo, serelaxin also reduced worsening heart failure (WHF) by 47% through day 5 and both all-cause and cardiovascular mortality by 37% through day 180. RELAX-AHF-2 ( ClinicalTrials.gov \u00a0NCT01870778) is designed to confirm serelaxin's effect on these clinical outcomes. RELAX-AHF-2 is a multicentre, randomized, double-blind, placebo-controlled, event-driven, phase 3 trial enrolling \u223c6800 patients hospitalized for AHF with dyspnoea, congestion on chest radiograph, increased natriuretic peptide levels, mild-to-moderate renal insufficiency, and systolic blood pressure \u2265125 mmHg. Patients are randomized within 16 h of presentation to 48 h intravenous infusions of serelaxin (30 \u00b5g\/kg\/day) or placebo, both in addition to standard of care treatments. The primary objectives are to demonstrate that serelaxin is superior to placebo in reducing: (i) 180 day cardiovascular death, and (ii) occurrence of WHF through day 5. Key secondary endpoints include 180 day all-cause mortality, composite of 180 day combined cardiovascular mortality or heart failure\/renal failure rehospitalization, and in-hospital length of stay during index AHF. The results from RELAX-AHF-2 will provide data on the potential beneficial effect of serelaxin on cardiovascular mortality and WHF in selected patients with AHF.<\/jats:p>","DOI":"10.1002\/ejhf.830","type":"journal-article","created":{"date-parts":[[2017,4,28]],"date-time":"2017-04-28T03:42:58Z","timestamp":1493350978000},"page":"800-809","source":"Crossref","is-referenced-by-count":112,"title":["Serelaxin in Addition to Standard Therapy in Acute Heart Failure: Rationale and Design of the RELAX-AHF-2 Study"],"prefix":"10.1093","volume":"19","author":[{"given":"John R.","family":"Teerlink","sequence":"first","affiliation":[{"name":"Section of Cardiology, San Francisco Veterans Affairs Medical Center and School of Medicine, University of California San Francisco \u00a0 San Francisco, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriaan A.","family":"Voors","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Medical Center Groningen Groningen,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Ponikowski","sequence":"additional","affiliation":[{"name":"Department of Heart Diseases, Medical University, Military Hospital , Wroclaw ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter S.","family":"Pang","sequence":"additional","affiliation":[{"name":"Indiana University School of Medicine, Department of Emergency Medicine and the Regenstrief Institute , Indianapolis, IN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry H.","family":"Greenberg","sequence":"additional","affiliation":[{"name":"Division of Cardiology, University of California , San Diego, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerasimos","family":"Filippatos","sequence":"additional","affiliation":[{"name":"Athens University Hospital Attikon , Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Michael","family":"Felker","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Duke University School of Medicine , Durham, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth A.","family":"Davison","sequence":"additional","affiliation":[{"name":"Momentum Research, Inc. , Durham, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gad","family":"Cotter","sequence":"additional","affiliation":[{"name":"Momentum Research, Inc. , Durham, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Gimpelewicz","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG , Basel ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leandro","family":"Boer-Martins","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation , East Hanover, NJ ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Wernsing","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation , East Hanover, NJ ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsushung A.","family":"Hua","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation , East Hanover, NJ ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Severin","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG , Basel ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Metra","sequence":"additional","affiliation":[{"name":"Cardiology, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia , Brescia ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,4,28]]},"reference":[{"key":"2026011721184701300_ejhf830-bib-0001","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.592","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"18","author":"Ponikowski","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026011721184701300_ejhf830-bib-0002","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"62","author":"Yancy","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026011721184701300_ejhf830-bib-0003","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1161\/HHF.0b013e318291329a","article-title":"Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association","volume":"6","author":"Heidenreich","year":"2013","journal-title":"Circ Heart Fail"},{"key":"2026011721184701300_ejhf830-bib-0004","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1001\/archinternmed.2012.3310","article-title":"The causes, treatment, and outcome of acute heart failure in 1006 Africans from 9 countries","volume":"172","author":"Damasceno","year":"2012","journal-title":"Arch Intern Med"},{"key":"2026011721184701300_ejhf830-bib-0005","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/ejhf.319","article-title":"Heart failure as a general pandemic in Asia","volume":"17","author":"Shimokawa","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"2026011721184701300_ejhf830-bib-0006","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1472-8206.2009.00697.x","article-title":"Early worsening heart failure in patients admitted with acute heart failure\u2014a new outcome measure associated with long-term prognosis?","volume":"23","author":"Weatherley","year":"2009","journal-title":"Fundam Clin Pharmacol"},{"key":"2026011721184701300_ejhf830-bib-0007","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.cardfail.2009.04.001","article-title":"Early worsening heart failure in patients admitted for acute heart failure: time course, hemodynamic predictors, and outcome","volume":"15","author":"Torre-Amione","year":"2009","journal-title":"J Card Fail"},{"key":"2026011721184701300_ejhf830-bib-0008","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1093\/eurjhf\/hfq132","article-title":"Dyspnoea and worsening heart failure in patients with acute heart failure: results from the Pre-RELAX-AHF study","volume":"12","author":"Metra","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"2026011721184701300_ejhf830-bib-0009","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jchf.2012.12.004","article-title":"Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure","volume":"1","author":"Packer","year":"2013","journal-title":"JACC Heart Fail"},{"key":"2026011721184701300_ejhf830-bib-0010","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/ejhf.308","article-title":"Early vs. late worsening heart failure during acute heart failure hospitalization: insights from the PROTECT trial","volume":"17","author":"Mentz","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"2026011721184701300_ejhf830-bib-0011","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jacc.2012.09.038","article-title":"Rehospitalization for heart failure: problems and perspectives","volume":"61","author":"Gheorghiade","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026011721184701300_ejhf830-bib-0012","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/ejhf.211","article-title":"Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction","volume":"17","author":"Kristensen","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"2026011721184701300_ejhf830-bib-0013","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1161\/CIRCULATIONAHA.107.696906","article-title":"Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure","volume":"116","author":"Solomon","year":"2007","journal-title":"Circulation"},{"key":"2026011721184701300_ejhf830-bib-0014","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.cardfail.2007.12.001","article-title":"Incident heart failure hospitalization and subsequent mortality in chronic heart failure: a propensity-matched study","volume":"14","author":"Ahmed","year":"2008","journal-title":"J Card Fail"},{"key":"2026011721184701300_ejhf830-bib-0015","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1093\/eurjhf\/hft032","article-title":"Risk following hospitalization in stable chronic systolic heart failure","volume":"15","author":"Abrahamsson","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"2026011721184701300_ejhf830-bib-0016","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nrcardio.2009.198","article-title":"Cardiovascular effects of relaxin: from basic science to clinical therapy","volume":"7","author":"Du","year":"2010","journal-title":"Nat Rev Cardiol"},{"key":"2026011721184701300_ejhf830-bib-0017","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1152\/physrev.00001.2012","article-title":"Relaxin family peptides and their receptors","volume":"93","author":"Bathgate","year":"2013","journal-title":"Physiol Rev"},{"key":"2026011721184701300_ejhf830-bib-0018","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1136\/heartjnl-2014-306786","article-title":"Serelaxin and acute heart failure","volume":"102","author":"Tietjens","year":"2016","journal-title":"Heart"},{"key":"2026011721184701300_ejhf830-bib-0019","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(12)61855-8","article-title":"RELAXin in Acute Heart Failure (RELAX-AHF) Investigators. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial","volume":"381","author":"Teerlink","year":"2013","journal-title":"Lancet"},{"key":"2026011721184701300_ejhf830-bib-0020","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.jacc.2012.11.005","article-title":"Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes","volume":"61","author":"Metra","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026011721184701300_ejhf830-bib-0021","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/S0140-6736(09)60622-X","article-title":"Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study","volume":"373","author":"Teerlink","year":"2009","journal-title":"Lancet"},{"key":"2026011721184701300_ejhf830-bib-0022","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/sim.3495","article-title":"A graphical approach to sequentially rejective multiple test procedures","volume":"28","author":"Bretz","year":"2009","journal-title":"Stat Med"},{"key":"2026011721184701300_ejhf830-bib-0023","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.jacc.2016.05.011","article-title":"2016 ACC\/AHA\/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America","volume":"68","author":"Yancy","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2026011721184701300_ejhf830-bib-0024","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/ejhf.294","article-title":"Agents with vasodilator properties in acute heart failure: how to design successful trials","volume":"17","author":"Mebazaa","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"2026011721184701300_ejhf830-bib-0025","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1161\/CIRCHEARTFAILURE.114.001536","article-title":"Renal hemodynamic effects of serelaxin in patients with chronic heart failure: a randomized, placebo-controlled study","volume":"7","author":"Voors","year":"2014","journal-title":"Circ Heart Fail"},{"key":"2026011721184701300_ejhf830-bib-0026","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/eurheartj\/ehs196","article-title":"Cinaciguat, a soluble guanylate cyclase activator, unloads the heart but also causes hypotension in acute decompensated heart failure","volume":"34","author":"Erdmann","year":"2013","journal-title":"Eur Heart J"},{"key":"2026011721184701300_ejhf830-bib-0027","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1159\/000093612","article-title":"ADHERE Study Group. Impact of early initiation of intravenous therapy for acute decompensated heart failure on outcomes in ADHERE","volume":"107","author":"Peacock","year":"2007","journal-title":"Cardiology"},{"key":"2026011721184701300_ejhf830-bib-0028","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1093\/eurheartj\/ehp458","article-title":"The impact of early standard therapy on dyspnoea in patients with acute heart failure: the URGENT-dyspnoea study","volume":"31","author":"Mebazaa","year":"2010","journal-title":"Eur Heart J"},{"key":"2026011721184701300_ejhf830-bib-0029","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1001\/jama.298.17.2009","article-title":"Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials","volume":"298","author":"McMurray","year":"2007","journal-title":"JAMA"},{"key":"2026011721184701300_ejhf830-bib-0030","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa0912613","article-title":"Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure","volume":"363","author":"Massie","year":"2010","journal-title":"N Engl J Med"},{"key":"2026011721184701300_ejhf830-bib-0031","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1161\/CIRCHEARTFAILURE.113.001281","article-title":"Influence of previous heart failure hospitalization on cardiovascular events in patients with reduced and preserved ejection fraction","volume":"7","author":"Bello","year":"2014","journal-title":"Circ Heart Fail"},{"key":"2026011721184701300_ejhf830-bib-0032","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1093\/eurheartj\/eht497","article-title":"Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial","volume":"35","author":"Filippatos","year":"2014","journal-title":"Eur Heart J"},{"key":"2026011721184701300_ejhf830-bib-0033","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1056\/NEJM200101043440103","article-title":"The pathogenesis of acute pulmonary edema associated with hypertension","volume":"344","author":"Gandhi","year":"2001","journal-title":"N Engl J Med"},{"key":"2026011721184701300_ejhf830-bib-0034","first-page":"CD005151","article-title":"Nitrates for acute heart failure syndromes","volume":"8","author":"Wakai","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"2026011721184701300_ejhf830-bib-0035","article-title":"Acute Heart Failure: Diagnosing and Managing Acute Heart Failure in Adults. NICE Clinical Guideline 187, Methods, evidence and recommendations","author":"National Clinical Guideline Centre","year":"2014","journal-title":"London: National Institute for Health and Care Excellence"},{"key":"2026011721184701300_ejhf830-bib-0036","first-page":"1531","article-title":"Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial","volume":"287","author":"VMAC Investigators","year":"2002","journal-title":"JAMA"},{"key":"2026011721184701300_ejhf830-bib-0037","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S0735-1097(02)02968-6","article-title":"Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study","volume":"41","author":"Felker","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"2026011721184701300_ejhf830-bib-0038","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1159\/000249280","article-title":"Physician-determined worsening heart failure: a novel definition for early worsening heart failure in patients hospitalized for acute heart failure\u2014association with signs and symptoms, hospitalization duration, and 60-day outcomes","volume":"115","author":"Cotter","year":"2010","journal-title":"Cardiology"},{"key":"2026011721184701300_ejhf830-bib-0039","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1002\/ejhf.186","article-title":"Worsening heart failure, a critical event during hospital admission for acute heart failure: results from the VERITAS study","volume":"16","author":"Cotter","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"2026011721184701300_ejhf830-bib-0040","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.ahj.2015.04.007","article-title":"Worsening heart failure during hospitalization for acute heart failure: Insights from the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF)","volume":"170","author":"Kelly","year":"2015","journal-title":"Am Heart J"},{"key":"2026011721184701300_ejhf830-bib-0041","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1002\/ejhf.333","article-title":"In-hospital worsening heart failure","volume":"17","author":"Butler","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"2026011721184701300_ejhf830-bib-0042","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jchf.2015.01.007","article-title":"PROTECT and RELAX-AHF Executive Committees. Worsening heart failure following admission for acute heart failure: a pooled analysis of the PROTECT and RELAX-AHF studies","volume":"3","author":"Davison","year":"2015","journal-title":"JACC Heart Fail"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fejhf.830","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/19\/6\/800\/66328270\/eurjhf_19_6_800.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/19\/6\/800\/66328270\/eurjhf_19_6_800.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T02:20:32Z","timestamp":1768702832000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/19\/6\/800\/8418597"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,28]]},"references-count":42,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2017,4,28]]},"published-print":{"date-parts":[[2017,6,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.830","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,6]]},"published":{"date-parts":[[2017,4,28]]}}}